Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico

The following study, conducted in Puerto Rico, examined the feasibility of providing daily buprenorphine-naloxone (bup-nx) in prison and on release to 45 male inmates with histories of heroin addiction. Participants were assessed at study entry and at 1 month after release (N = 42; 93.3% follow-up rate). Treatment completers compared with noncompleters had significantly greater reductions in self-reported heroin use, cocaine use, and crime and were less likely to be opioid-positive according to urine drug testing. Despite study limitations, the short-term outcomes of this study suggest that bup-nx may contribute to reductions in readdiction to heroin and in criminal activities among re-entering male prisoners.

[1]  R. Heimer,et al.  Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. , 2006, Drug and alcohol dependence.

[2]  P. Friedmann,et al.  Attitudes and practices regarding the use of methadone in US State and federal prisons , 2005, Journal of Urban Health.

[3]  Crime..  HIV/Aids prevention, care, treatment and support in prison settings: a framework for an effective national response , 2006 .

[4]  D. J. James,et al.  Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002: (514862006-001) , 2005 .

[5]  J. Peugh,et al.  Estimating drug treatment needs among state prison inmates. , 2005, Drug and alcohol dependence.

[6]  M. Stitzer,et al.  Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users , 1994, Psychopharmacology.

[7]  S. Deren,et al.  HIV Incidence Among High-Risk Puerto Rican Drug Users: A Comparison of East Harlem, New York, and Bayamón, Puerto Rico , 2004, Journal of acquired immune deficiency syndromes.

[8]  R. D. Bruce,et al.  Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations , 2004 .

[9]  K. Preston,et al.  Randomized Trial of Buprenorphine for Treatment of Concurrent Opiate and Cocaine Dependence , 2004, Clinical pharmacology and therapeutics.

[10]  W. Ling,et al.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. , 2003, The New England journal of medicine.

[11]  L. Amass,et al.  Buprenorphine: how to use it right. , 2003, Drug and alcohol dependence.

[12]  W. Ling,et al.  The Clinical Opiate Withdrawal Scale (COWS) , 2003, Journal of psychoactive drugs.

[13]  Daniel P. Mears,et al.  Drug Treatment in the Criminal Justice System: The Current State of Knowledge , 2003 .

[14]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[15]  E. Strain.  Assessment and Treatment of Comorbid Psychiatric Disorders in Opioid-Dependent Patients , 2002, The Clinical journal of pain.

[16]  R. Schwartz,et al.  A novel opioid maintenance program for prisoners: preliminary findings. , 2002, Journal of substance abuse treatment.

[17]  Michael Berry,et al.  Office of National Drug Control Policy , 2002 .

[18]  S. Friedman,et al.  RESIDENTIAL STATUS AND HIV RISK BEHAVIORS AMONG PUERTO RICAN DRUG INJECTORS IN NEW YORK AND PUERTO RICO* , 2001, The American journal of drug and alcohol abuse.

[19]  A. Swanson,et al.  The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. , 2001, The Mount Sinai journal of medicine, New York.

[20]  R. E. Johnson,et al.  Buprenorphine and Naloxone for Heroin Dependence , 2000, Current psychiatry reports.

[21]  S. Stancliff,et al.  Methadone maintenance treatment (MMT): a review of historical and clinical issues. , 2000, The Mount Sinai journal of medicine, New York.

[22]  G. Gessa,et al.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. , 2000, Drug and alcohol dependence.

[23]  M L Brandeau,et al.  HIV transmission and the cost-effectiveness of methadone maintenance. , 2000, American journal of public health.

[24]  R. Jagsch,et al.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence , 1999, European Neuropsychopharmacology.

[25]  K. Preston,et al.  Acute administration of buprenorphine in humans: partial agonist and blockade effects. , 1995, The Journal of pharmacology and experimental therapeutics.

[26]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[27]  R. Needle,et al.  Modifying the process of treatment to meet the threat of AIDS. , 1994, The International journal of the addictions.

[28]  G. Badger,et al.  Alternate-day dosing during buprenorphine treatment of opioid dependence. , 1994, Life sciences.

[29]  P. Stolley,et al.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.

[30]  A. Rosenblum,et al.  The Effectiveness of In-Jail Methadone Maintenance , 1993 .

[31]  C. Leukefeld,et al.  The challenge of drug abuse treatment in prisons and jails. , 1992, NIDA research monograph.

[32]  D. Nurco,et al.  Contemporary issues in drug abuse treatment linkage with self-help groups. , 1991, NIDA research monograph.

[33]  Alan Ross,et al.  The Effectiveness of Methadone Maintenance Treatment , 1991, Springer New York.

[34]  F. J. Evans,et al.  New Data from the Addiction Severity Index Reliability and Validity in Three Centers , 1985, The Journal of nervous and mental disease.